Benefitting from Embedded Quality for End-to-End Success

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

Enzymatic Synthesis

Transforming Enzymatic Processes into Commercial-Scale Manufacturing

Kohei Mori

Kaneka

Pathfinder

Platform Development vs. Molecule-Specific Process Development: Which Strategy Is Better for Biologics?

Nice Insight

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

Biosimilars

The Global Division of Labor Behind the Coming Oncology Biosimilar Wave

Pharma's Almanac

Pathfinder

Enzymatic Synthesis vs. Fermentation for Biomanufacturing: Which Production Strategy Is Better?

Nice Insight

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika

CDMO Governance

The Governance Gap: Why Good CDMO Partnerships Still Fail

Pharma's Almanac

CDMO Consolidation

How Far Should CDMO Network Consolidation Go?

Pharma's Almanac